Bioink is a printable material made from living cells suspended in a supportive gel, designed specifically for 3D bioprinters that build living tissue layer by layer. Unlike the plastics or resins used in standard 3D printing, bioink must keep cells alive throughout the printing process and afterward, while holding a stable shape. The global bioink market is projected to reach about $99 million in 2026 and grow to $303 million by 2035, reflecting how quickly the field is expanding.
What Bioink Is Made Of
Every bioink has two essential parts: living cells and a carrier material that acts as scaffolding. The carrier is almost always a hydrogel, a water-rich polymer network that mimics the soft, wet environment cells naturally live in. Think of it as a biological jelly that holds cells in place while giving them room to grow, divide, and communicate with their neighbors.
The hydrogel portion can come from natural sources, synthetic ones, or a blend of both. Natural polymers like alginate (derived from seaweed), gelatin, collagen, hyaluronic acid, and cellulose derivatives are popular because cells tolerate them well. The tradeoff is that natural gels tend to be structurally weak, meaning printed shapes can sag or collapse. Synthetic polymers offer more mechanical strength and tunability but don’t always interact with cells as favorably. Hybrid bioinks that combine both types aim to get the best of each: strong enough to hold its shape, friendly enough for cells to thrive.
Cell densities in bioinks vary depending on the tissue being printed. Researchers have successfully printed with concentrations ranging from about 1.5 million cells per milliliter up to 40 million cells per milliliter without breaking the printed filament or clogging pores. Choosing the right density matters because too few cells won’t form functional tissue, while too many can interfere with the gel’s structural properties.
How Bioink Behaves During Printing
Bioink needs a somewhat contradictory set of physical properties. Inside the printer, it must flow smoothly through a narrow nozzle without killing cells from excessive pressure. Once deposited, it must immediately hold its shape and not spread into a puddle. The key property that makes this possible is called shear-thinning: the material gets thinner and flows more easily when force is applied (like being pushed through a nozzle), then thickens again as soon as that force stops. Alginate-based hydrogels, for instance, display this behavior naturally.
An ideal bioink is also highly thixotropic, meaning its viscosity drops rapidly under pressure but recovers almost instantly once the pressure is removed. This quick recovery is what allows each printed layer to support the next one without slumping. Getting this balance wrong means either a clogged nozzle or a structure that collapses under its own weight.
How Printed Structures Become Solid
Once a bioink is deposited, it usually needs an extra step to lock the structure in place permanently. This process, called crosslinking, creates bonds between polymer chains so the gel becomes a stable 3D network. There are three main approaches.
- Light-based crosslinking uses ultraviolet, visible, or laser light to trigger chemical bonds in the gel. This is fast and gives precise control over which areas solidify, but requires adding light-sensitive molecules to the bioink.
- Chemical crosslinking involves adding a reactive agent, like a calcium salt for alginate gels, that permanently bonds the polymer chains together through covalent bonds. These bonds are strong and irreversible.
- Thermal crosslinking relies on temperature changes. Agarose, for example, forms a gel when cooled below about 32°C, as its polymer chains shift from a loose, random arrangement into an organized helical structure. Other materials do the opposite, gelling when warmed to body temperature (37°C).
The crosslinking method has to be gentle enough not to harm the embedded cells. Exposing living cells to harsh chemicals, extreme heat, or prolonged UV light can kill them, so researchers carefully calibrate intensity and duration. In well-optimized bioinks, cell survival rates can reach 95% or higher even three weeks after printing.
What Bioink Is Being Used to Build
The ultimate goal of bioink is to print functional human tissues and, eventually, transplantable organs. Researchers have made significant progress with several tissue types. Bone organoids have been engineered using bioinks containing mineral particles, producing structures that mineralize on their own and form realistic bone architecture when implanted in animal models. Cartilage organoids printed with specialized bioinks have shown enhanced mechanical strength and successfully restored layered cartilage structure in defect models. Researchers have also built neuro-osseous constructs (bone tissue integrated with nerve pathways) using dual-channel bioprinters, opening new approaches for repairing bone injuries where nerve regeneration is also needed.
Skin is another active area. Because skin is relatively thin and has a simpler structure than solid organs, it’s one of the more achievable targets. Bioprinted skin grafts are being tested for wound healing and burn treatment. Cartilage, similarly, benefits from being avascular (it has no blood vessels), which sidesteps one of the field’s biggest challenges.
The Blood Vessel Problem
The single largest obstacle to printing thick, complex tissues is vascularization: getting blood vessels into the printed structure. Oxygen can only diffuse about 100 to 200 micrometers into tissue before cells start starving. Anything thicker than that without a blood supply develops dead zones. Natural blood vessel growth in the body is slow, advancing only a few tens of micrometers per day, which means an implanted construct could remain unvascularized for weeks.
Researchers are tackling this from multiple angles. One strategy involves printing sacrificial channels into the structure that serve as templates for future blood vessels. Another uses endothelial cells (the cells that line blood vessels) mixed into the bioink, relying on their natural tendency to self-organize into capillary-like networks. Some teams embed growth factors that attract blood vessel formation after implantation. Bioprinting offers a particular advantage here because it can precisely position these vascular elements within the tissue, rather than relying on random growth from the outside in. Still, building a fully vascularized organ with arteries, veins, and capillaries remains an unsolved problem.
Regulatory Status
No bioink-based product has received full regulatory approval for clinical use. The regulatory path is complicated because bioinks don’t fit neatly into existing categories. Both the FDA and EU frameworks would classify them as combination products, since they merge biological components (living cells, growth factors) with a medical device (the hydrogel and its delivery system). Current regulations address devices for specific applications, not the raw materials themselves, which creates ambiguity around how bioinks should be evaluated.
One notable milestone was Aurinovo, a bioprinted ear implant that entered clinical trials. While the trial demonstrated the feasibility of bioprinted implants in humans, the company later discontinued the product for reasons unrelated to safety. That decision illustrates the gap between technical possibility and commercial viability. The path from laboratory success to approved medical product remains long, with questions about manufacturing consistency, long-term safety, and quality control still being worked out.